Therapeutic potential of resveratrol in heart failure

Ann N Y Acad Sci. 2015 Aug;1348(1):32-45. doi: 10.1111/nyas.12839. Epub 2015 Jul 23.

Abstract

Despite existing therapies, patients with heart failure have a very poor quality of life and a high 1-year mortality rate. Given the impact of this syndrome on health outcomes, research is being directed toward identifying novel strategies to treat heart failure symptoms as well as to prolong survival. One molecule that has been tested in animal models for this purpose is resveratrol. Resveratrol is a naturally occurring polyphenol found in several plants, and administration of resveratrol has been shown to prevent and/or slow the progression of heart failure in animal models of heart failure induced by myocardial infarction, pressure overload, myocarditis, and chemotherapy-induced cardiotoxicity. In addition, some animal studies have shown that resveratrol improves cardiac function and survival when administered as a treatment for established heart failure. Furthermore, as heart failure induces alterations in skeletal muscle and vasculature that also contribute to certain heart failure symptoms, such as fatigue and exercise intolerance, it has also been shown that resveratrol acts on these peripheral tissues to improve skeletal muscle and endothelial/vascular function. Therefore, if these animal studies translate to humans, resveratrol may prove to be a novel therapy for the treatment of heart failure.

Keywords: AMPK; exercise; heart failure; remodeling; resveratrol.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiotonic Agents / pharmacokinetics
  • Cardiotonic Agents / pharmacology
  • Cardiotonic Agents / therapeutic use*
  • Heart Failure / drug therapy
  • Heart Failure / prevention & control*
  • Humans
  • Resveratrol
  • Stilbenes / pharmacokinetics
  • Stilbenes / pharmacology
  • Stilbenes / therapeutic use*

Substances

  • Cardiotonic Agents
  • Stilbenes
  • Resveratrol